Mycetoma is a tropical neglected disease characterized by large subcutaneous lesions in which the causative organisms reside in the form of grains. The most common causative agent is Madurella mycetomatis. Antifungal therapy often fails due to these grains, but to identify novel treatment options has been difficult since grains do not form in vitro. We recently used Galleria mellonella larvae to develop an in vivo grain model. In the current study, we set out to determine the therapeutic efficacy of commonly used antifungal agents in this larval model. Pharmacokinetics of ketoconazole, itraconazole, voriconazole, posaconazole, amphotericin B, and terbinafine were determined in the hemolymph of G. mellonella larvae. Antifungal therapy was given either therapeutically or prophylactic on three consecutive days in therapeutically equivalent dosages. Survival was monitored for 10 days and colony-forming units (cfu) and melanization were determined on day 3. Measurable concentrations of antifungal agents were found in the hemolymph of the larvae. None of the azole antifungal agents prolonged survival when given therapeutically or prophylactically. Amphotericin B and terbinafine did prolong survival, even at concentrations below the minimal inhibitory concentration of M. mycetomatis. The cfu and melanization did not differ between any of the treated groups and phosphate-buffered saline (PBS) treated groups. Grains were still present in surviving larvae but appeared to be encapsulated. This study demonstrated for the first time a comparison between the efficacy of different antifungal agents toward grains of M. mycetomatis. It appeared that amphotericin B and terbinafine were able to prolong larval survival.
Introduction
Mycetoma is a tropical neglected disease characterized by large subcutaneous lesions in which the causative organisms resides in the forms of granules called grains. 1 Mycetoma can be caused by a large variety of micro-organisms, both fungi (eumycetoma) and bacteria (actinomycetoma). Globally, the most common causative agent is the fungus Madurella mycetomatis. 2 Therapy for actinomycetoma and eumycetoma differs. Actinomycetoma is treated with antibiotic agents only, and only rarely surgery is needed. This has a very high success rate, with 90% of patients cured. 3 In contrast, eumycetoma is treated with a combination of antifungal therapy and surgery, and the success rates are disappointing. Up until 2013, eumycetoma treatment consisted of 6 months treatment with ketoconazole, followed by surgery. To prevent recurrent infections, another year of antifungal therapy with ketoconazole was given. 3 Even with this prolonged treatment with high doses of ketoconazole, treatment success rates are poor. For ketoconazole, only a 25.9% cure rate has been reported. 4 Since 2013, itraconazole has become the drug of choice, since the EMA, the FDA, and the Sudan government has suspended the use of ketoconazole for the treatment of fungal infections due to the severe toxic side effects. 3, 5, 6 Currently, there are no data available on the cure rates for itraconazole, but similar cure rates as for ketoconazole are to be expected based on the two small clinical studies in which therapy success rates for ketoconazole 7 and itraconazole 8 were investigated. Based on these low cure rates and relative high toxicity rates, there is a need to find alternative treatment options for mycetoma. Currently, the azole class of antifungal agents is not the only class of antifungal agents in use to treat fungal infections. Cutaneous infections are often treated with terbinafine and severe systemic infections are also treated with either amphotericin B or one of the echinocandins. In in vitro studies, we exposed hyphal fragments of M. mycetomatis toward these antifungal agents and demonstrated that this fungus is highly susceptible toward the azoles, 9, 10 less susceptible toward amphotericin B 10 and terbinafine, 9 and resistant toward the echinocandins. 11 A limitation of these in vitro studies is that we need to expose hyphae toward the antifungal agents since it is not possible to form grains in vitro. However, fungal grains differ considerably from hyphae. Within the grain, hyphae are embedded in a hard cement material which could act as a physical barrier for the antifungal agents. Therefore, in vitro susceptibility data might not be indicative for clinical success or failure in the patient. A grain model would give us more insight to the susceptibility of fungal grains toward antifungal agents. Recently, we developed a grain model in larvae of the wax moth Galleria mellonella. 12 Within these larvae, grains are formed within 4 hours after inoculation with M. mycetomatis. These grains resembled the grains formed in humans, and cement material was formed within 3 days. Therefore, this model could be of use to determine the therapeutic efficacy of various antifungal agents toward the M. mycetomatis grain.
In this study, we determined the therapeutic efficacy of antifungal agents with in vitro activity against M. mycetomatis in the previously published grain model in G. mellonella larvae. We determined if ketoconazole, itraconazole, voriconazole, posaconazole, amphotericin B, and terbinafine were able to prolong the survival of G. mellonella larvae when treatment was started either before or after inoculation with M. mycetomatis.
Methods

G. mellonella larvae
Final sixth instar G. mellonella larvae were acquired from Vellinga Voedseldieren (Ridderkerk, The Netherlands) or FizzDizz (Geesteren, The Netherlands) and kept at room temperature on wood shavings in the dark until use. Larvae were used within 5 days of receipt. Larvae of approximately 300 to 500 mg showing no discoloration were selected for the experiments.
In vitro susceptibility testing
To determine the in vitro susceptibility of strain Mm55 against amphotericin B deoxycholate (Fungizone, BristolMyers Squibb, Utrecht, The Netherlands), ketoconazole (Janssen pharamceutica, Beerse, Belgium), itraconazole (Janssen pharamceutica, Beerse, Belgium), voriconazole (Vfend, Pfizer, Capelle aan den Ijsel, The Netherlands), posaconazole (Merck, Darmstadt, Germany,) and terbinafine (Novartis, Arnhem, The Netherlands) a previously developed assay was used. 10, 13 Preparation of antifungal agents and tolerability in G. mellonella larvae
The pharmacokinetics of amphotericin B, ketoconazole, itraconazole, voriconazole, posaconazole, and terbinafine were determined after the administration of a single dose to uninfected G. mellonella larvae. Amphotericin B deoxycholate (Fungizone) was diluted in a 5% glucose solution to a final concentration of 25 μg/ml. Ketoconazole, itraconazole and posaconazole (reference compounds) were dissolved in dimethylsulfoxide (DMSO) and further diluted in phosphate buffered saline (PBS) to a final concentration of 140 μg/ml. Voriconazole (Vfend) was dissolved in aquadest and further diluted in phosphate-buffered saline (PBS) to a final concentration of 140 μg/ml. Terbinafine (reference compound) was dissolved in DMSO and further diluted in 5% glucose solution to a final concentration of 357 μg/ml. For all compounds dissolved in DMSO, the final DMSO concentration was 5%, a concentration which was well tolerated by the larvae. Each larva was injected with 20 μl of antifungal solution, which resulted in a final concentration of 1 mg/kg for amphotericin B, 5.7 mg/kg for ketoconazole, itraconazole, posaconazole, and voriconazole and 7.14 mg/kg for terbinafine. Based on literature, this is comparable to the amount of mg/kg given in humans during infection. 3, [14] [15] [16] To determine if larvae could tolerate these doses, groups of 15 larvae were treated with these antifungal agents. Each larva received three doses in total with an interval of 24 h. Survival was monitored for 10 days.
Pharmacokinetics of antifungal agents in G. mellonella larvae
To determine the pharmacokinetics of these antifungal agents, for each antifungal agent 70 larvae were used. Larvae received a single dose of antifungal agent and were killed at 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, and 24 h after administration. Hemolymph was obtained from 10 larvae and pooled. The concentration of ketoconazole, amphotericin B, and terbinafine were determined by a well diffusion assay. The indicator micro-organism was streaked onto plates with a cotton swab, and wells were then punched into the agar with a cork borer. Plates differed for each antifungal agent to be tested. Diagnostic Sensitivity Test (DST) agar (Oxoid, Badhoevedorp, The Netherlands) was used to test ketoconazole concentrations, Müller-Hinten agar (Becton Dickinson, Breda, The Netherlands) was used to test amphotericin B concentrations and Sabouraud agar (Becton Dickinson, Breda, The Netherlands) was used to test terbinafine concentrations. Candida albicans was used as an indicator micro-organism for ketoconazole, amphotericin B and terbinafine. Antifungal standards of the appropriate range, including a control in which no antifungal agent was present, were prepared in a 1:1 diluted haemolymph of uninfected and non-treated larvae in IPS buffer (Insect Physiological Saline: 150 mM sodium chloride, 5 mM potassium chloride, 10 mM Tris-HCl pH 6.9, 10 mM EDTA, and 30 mM sodium citrate). Haemolymph of larvae receiving a single dose of antifungal agent were also diluted 1:1 in IPS buffer. From each solution (standard or sample) 100 μl was placed into a well in triplicate. Plates were incubated at 37
• C overnight, and inhibition zones were measured. Based on the inhibition zones of the standards, the antifungal concentration in hemolymph was calculated.
The concentration of itraconazole, voriconazole, and posaconazole were determined by a validated ultraperformance liquid chromatography (UPLC) method with fluorescence detection. Details of the analytical assay are described elsewhere. 17 Briefly, samples were pretreated using a protein precipitation procedure (acetonitrile-methanol, 50/50, and formic acid, 0.1%). A seven-point calibration curve with three quality control (QC) samples was used. All measurements were done in duplicate. The assay was validated over the concentration range of 0.050-10,000 mg/l for all azoles. The accuracies for the assay were 97-104%, interand intra-day coefficients of variation were <7.5%, and extraction recoveries were 98% for voriconazole, posaconazole, and 79% for itraconazole, respectively. The area under the hemolymph plasma concentration-versustime curve (AUC) over 24 h (AUC24) and the Cmax were calculated using GraphPad Prism 5 (version 5.03, GraphPad Inc.).
Infection of G. mellonella larvae with M. mycetomatis and antifungal treatment
G. mellonella larvae were infected with M. mycetomatis isolate Mm55 according to the previously published protocol. 12 In short, M. mycetomatis mycelia were cultured in colorless RPMI 1640 medium supplemented with L-glutamin (0.3 g/l), 20 mM mopholinepropanesulfonic acid (MOPS) and chloramphenicol (100 mg/l; Oxoid, Basingstroke, United Kingdom) for 2 weeks at 37
• C and sonicated for 2 min at 28 micron. The resulting homogenous suspension was washed once in PBS and further diluted to an inoculum size of 4 mg wet weight per larvae. Inoculation was performed by injecting 40 μl of the fungal suspension in the last left pro-leg with an insulin 29 G U-100 needle (BD diagnostics, Sparsk, Nevada, USA). As controls larvae injected with PBS or 5% glucose were included. Larvae were treated with either 1 mg/kg amphotericin B, 5.7 mg/kg ketoconazole, 5.7 mg/kg itraconazole, 5.7 mg/kg voriconazole, 5.7 mg/kg posaconazole, 7.14 mg/kg terbinafine, PBS or 5% glucose. Each larva received three injections of antifungal agent. For therapeutic purposes, antifungal agents were administered 4 h, 28 h, and 52 h after infection. Treatment was started at 4 h since at that time point grains were already visible. For prophylactic purposes, antifungal agents were administered 2 h before and 24 h and 48 h after infection. To monitor the course of infection, larvae were checked daily for survival for 10 days. If during these 10 days larvae formed pupa, these individuals were left out of the equation, since we could not ascertain that these individual larvae would have survived or died during the infection. At day 3 and day 10 after inoculation larvae were dissected to determine if black grains were present by macroscopic observation and histology. If grains were present, culture on Sabouraud agar was performed to determine their viability.
Histology
For histological observations, larvae were fixed in 10% buffered formalin. Since the larval exoskeleton is impenetrable to most fixative reagents, 100 μl of the 10% buffered formalin was injected into the larvae. 18 After 24 h fixation, whole larvae were dissected longitudinally into two halves with a scalpel and fixated in 10% formalin for at least another 48 h. 18 The two halves of larvae were routinely processed for histology. Sections were stained with hematoxylin and eosin (HE), Grocott methanamine silver and Sirius red.
Fungal burden
To determine the fungal burden, five larvae from each group were killed at day 3 post infection. First, haemolymph was collected and measured as described earlier 12 to assess melanization. To assess the number of colony forming units (cfu) per larvae, 10 chrome steal metal balls and 1 ml PBS were added. Larvae were homogenized in a Qiagen Tissue lyser for 5 min at 30 Hz. From each homogenized larva 250 μl undiluted, 50 μl undiluted, and 50 μl 1 : 10 diluted suspension was plated out on Sabouraud-gentamicin agar.
Plates were incubated at 37
• C for 2 weeks and the number of cfu per larvae was determined.
Statistical analysis
To compare the survival curves the Log-rank test was performed with GraphPad Prism 5 (version 5.03, GraphPad Inc. 
Results
Establishment of human pharmacokinetic equivalent dosages in larvae of G. mellonella.
In the literature, it was already described that M. mycetomatis is susceptible toward amphotericin B, the azoles, and terbinafine, but not toward the echinocandins and 5-flucytosine. Strain mm 55 was most susceptible toward the azole antifungal agents, with MICs of 0.25 μg/ml for ketoconazole and itraconazole and 0.125 μg/ml for voriconazole and posaconazole. Higher MICs were obtained for amphotericin B (2 μg/ml) and terbinafine (16 μg/ml). Therefore, to determine which antifungal agent had therapeutic efficacy against M. mycetomatis grains, we tested the efficacy of amphotericin B, ketoconazole, itraconazole, voriconazole, posaconazole, and terbinafine in our grain model in G. mellonella larvae. For amphotericin B the Cmax/MIC ratio is considered the PK/PD index determining therapeutic efficacy, while for the azoles this is the AUC/MIC ratio. 19 For terbinafine this has not been established. 20 Therefore, we aimed at reaching a Cmax for amphotericin B and an AUC for the azoles in our G. mellonella larvae which was comparable to those obtained in human. Concentrations of antifungal agents were present during 24 h after injection (Fig. 1) . Only for the azoles, the concentrations obtained in hemolymph were above the MIC. Concentrations of amphotericin B and terbinafine in hemolymph never exceeded the MIC. In Table 1 , the measured AUC 24h and C max for each drug in the hemolymph for G. mellonella are stated. As is seen in this table, Cmax for amphotericin B in hemolymph was comparable to the Cmax seen in human serum. The AUC 24h of posaconazole in hemolymph was comparable to the AUC 24h in human serum. The AUC 24h for ketoconazole (1.46% of human AUC) and itraconazole (61.9% of human AUC) were lower in G. mellonella larvae than in humans, but higher concentrations could not be obtained due to problems with the solubility of the drug. For voriconazole a higher AUC 24h was obtained in hemolymph (288.5% of human AUC).
Therapeutic efficacy of antifungal treatment
After infecting G. mellonella larvae with M. mycetomatis strain mm55, larvae were treated with itraconazole and ketoconazole, the drugs currently used to treat mycetoma. Treatment started at 4 h past inoculation, a time-point at which fungal grains were formed. Itraconazole and ketoconazole did not enhance larval survival (Log Rank, P = NS), only 3 out of 45 larvae survived in both cases ( Fig. 2A) . Since in European countries, mycetoma patients are usually treated with voriconazole or posaconazole we wondered if these drugs would be more effective than ketoconazole and itraconazole. However, treatment with voriconazole and posaconazole also did not result in enhanced survival in G. mellonella larvae infected with M. mycetomatis (Fig. 2B) . Only switching to another class of antifungal agents resulted in enhanced survival. Enhanced survival was noted when infected G. mellonella larvae were treated with amphotericin B (Log-Rank, P = .0014) or terbinafine (Log-Rank, P = .010) (Fig. 2C and 2D ). To determine if treatment with these antifungal agents would reduce the burden of infection, the number of CFU per larvae were determined on day 3. No difference was found among the different groups (Kruskall-Wallis, P = .089) (Fig. 2E) . Furthermore, no difference was found among the different groups in terms of melanization of larvae (Kruskal-Wallis, P = .10) (Fig. 2F) . On day 10, surviving larvae were prepared for histology. It appeared that grains were still present inside the larvae but that they were encapsulated. There was no sign of immune cells attracted to grains, as was seen in late infection in nontreated larvae. 12 Furthermore, the encapsulation was irrespective of the class of antifungal agents used. The same phenomenon was seen for the azoles, amphotericin B and terbinafine (Fig. 3) .
Prophylactic efficacy of antifungal treatment
Since in the treatment of mycetoma, antifungal therapy is given before and after surgery, it is also important to know if these antifungal agents are able to prevent grain formation. Therefore, the prophylactic efficacy of the antifungal agents was also determined in our larval model. To study the prophylactic potential, treatment started 2 hours before inoculation with M. mycetomatis. At that time point, high levels of itraconazole, voriconazole and amphotericin B are found in the hemolymph (Fig. 1) . For posaconazole and terbinafine, relatively low levels are found in the hemolymph at this time point, but these levels were still higher than the MIC for posaconazole (Fig. 1) . For ketoconazole, very low levels were found, concentrations were lower than the MIC (Fig. 1) . As can be seen in figure 4 , the azoles ketoconazole, itraconazole and posaconazole did not result in enhanced survival of G. mellonella larvae infected with M. mycetomatis (Log-Rank, P > .05). Also, voriconazole prophylaxes had no effect, although a trend towards enhanced survival was noted (Log-Rank, P = .07). Again, only for amphotericin B and terbinafine, enhanced survival was noted (Log-Rank, p = .04 for amphotericin B and for terbinafine). The number of cfu/larvae differed among the different groups (Kruskal-Wallis, P = .0009). Strikingly, only larvae treated with ketoconazole (Mann-Whitney, P = .0079) and itraconazole (Mann-Whitney, P = .0079) had lower cfu/larvae than the PBS treated group, while the larvae treated with voriconazole, posaconazole, amphotericin B, and terbinafine had similar CFU/larvae as the PBS treated group (Mann-Whitney, P > .05) (Fig. 4E ). An 11.5-fold reduction was noted for ketoconazole, while for itraconazole an 9.6-fold reduction was noted. Melanization of the larvae did not differ between the different groups (Kruskal-Wallis, P = .76) (Fig. 4F) .
Discussion
In the current study, we showed that only amphotericin B and terbinafine enhanced the survival of G. mellonella larvae infected with M. mycetomatis. No enhanced survival was noted when larvae were treated with the azoles, the drugs currently used to treat mycetoma. In vitro, M. mycetomatis appeared to be most susceptible towards the azoles and less towards amphotericin B and terbinafine.
9,10 Strikingly, enhanced survival with amphotericin B or terbinafine was even noted at concentrations of each antifungal agent in hemolymph below the measured MIC. In in vitro susceptibility assays, M. mycetomatis hyphal fragments are exposed to antifungal agents, while in vivo grains are present. Indeed, Murray and Colichon already demonstrated in 1962, that hyphae exposed to amphotericin B were inhibited in growth, but grains freshly isolated from infected mice were not. 21 We therefore also determined if prophylactic treatment of antifungal agents could enhance larval survival. Based on the pharmacokinetic profile we demonstrated that when the antifungal agents were given 2 h before infection, concentrations above the MIC are still present in the hemolymph for itraconazole, posaconazole, and voriconazole. Since we inoculate with a hyphal suspension, the antifungal agents should be able to inhibit the growth. But as seen in Figure 4 , no enhanced survival was noted for any of the azoles, only amphotericin B enhanced survival. Even with prophylactic therapy, grains did develop and the number of cfu was hardly reduced.
Only for ketoconazole and itraconazole a significant reduction in cfu was noted after prophylactic treatment, not for the other drugs.
Although in this larval model we demonstrated that only amphotericin B and terbinafine are able to prolong survival of G. mellonella larvae, it remains a question if these results are predictive for the therapeutic outcome in patients. The model used here is a lethal model, while in man mycetoma caused by M. mycetomatis is usually not lethal. Also, the mouse model developed by Ahmed et al. is a nonlethal model, 22 but it might be the best model to compare our results with. In both our larval model, and the mouse model of Ahmed et al., genome strain mm55 is used. 12, 22 In the mouse model of Ahmed et al., only the therapeutic efficacy of itraconazole and amphotericin B were studied. When treatment was started 1 h after inoculation of M. mycetomatis and continued for 14 days, grain formation was observed only in the itraconazole group, not in the amphotericin B group. 23 So in both models, amphotericin B seemed superior over the azoles in the treatment of mycetoma. Also in patients, azoles in general are not able to completely cure mycetoma. In a recently published prospective study performed in the Mycetoma Research Centre in Khartoum, Sudan, 1242 eumycetoma patients were treated with ketoconazole, the drug of choice at that time. Out of these 1242 patients, only 321 were cured. 4 When the recommended treatment was switched to itraconazole in 2013 3, 5, 6, 8 in most endemic countries and to voriconazole and posaconazole in Europe and South America, 16, 24, 25 still partial improvement treatment was noted. 8, 24, 25 Viable grains could still be retrieved from the lesions, even after long courses of treatment with azoles (>18 months), indicating that in human lesions the azole agents are not able to kill mycetoma grains. 8 This is in agreement with the results obtained in our G. mellonella model. In our study, we demonstrated that ketoconazole, itraconazole, voriconazole, and posaconazole did not enhance G. mellonella survival and that grains were still present at the end of the observation period. Moreover, in the surviving larvae, grains were encapsulated. Also in patients, lesions were encapsulated with thick capsules which were not found in patients not treated with itraconazole. 8 For amphotericin B, hardly any data on the efficacy in patients has been published. It is no longer used and indicated only sporadically with limited success due to its adverse effects. 26 Next to amphotericin B, enhanced survival of G. mellonella larvae infected with M. mycetomatis was also was found when larvae were treated with terbinafine. In patients, terbinafine is not often used. There is only one study in which a larger cohort of patients is treated with terbinafine. In that study terbinafine treatment only resulted in partial response and in 12 out of 20 patients, fungi could still be cultured after prolonged therapy. 14 The general outcome in patients treated with terbinafine appeared to be similar to that of patients treated with azoles. This seems to be in contradiction to the results obtained in our larval model. Although grains are still present at the end of 14 mg/kg terbinafine. Statistical significance was calculated with Log-Rank test. * , Log-Rank, P = .04. Next to survival also some secondary parameters of therapeutic efficacy were measured.
These included E: the number of colony forming units (cfu) per larvae and F: melanization of hemolymph. Statistical significance was determined with the Kruskal-Wallis and subsequently the Mann-Whitney test. treatment, enhanced survival indicated that terbinafine indeed had some potential in the treatment of mycetoma.
In conclusion, we demonstrated that only amphotericin B and terbinafine could enhance the survival of G. mellonella larvae infected with M. mycetomatis while none of the azoles tested were able to do so. Further studies are needed to determine the predictive value of this model for the clinical situation.
